New Industry Report Asks Whether 2024 is Living Up to Expectations for Offshore Wind?
March 21, 2024 02:00 ET
|
TGS ASA
Lowestoft, UK (21 March 2024) — TGS, the leading global provider of energy data and intelligence, has released its latest Market Overview Report, powered by 4C Offshore market intelligence. This...
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
March 18, 2024 16:05 ET
|
Avenue Therapeutics
- Enrollment completed in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy; topline data expected in second quarter of 2024 - - Presented positive BAER-101 preclinical...
Avenue Therapeutics Receives Positive Listing Determination from Nasdaq
March 15, 2024 08:15 ET
|
Avenue Therapeutics
MIAMI, March 15, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of...
Organic's best honored at "An Organic Night Out"
March 14, 2024 15:22 ET
|
The Organic Center
ANAHEIM, CA, March 14, 2024 (GLOBE NEWSWIRE) -- The organic community gathered Wednesday night at the Natural Products Expo West trade show in an inspiring and joyful celebration to honor the best...
Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting
March 11, 2024 08:00 ET
|
Avenue Therapeutics
BAER-101 demonstrated full suppression of seizure activity in SynapCell's GAERS model of absence epilepsy, a proven indicator of efficacy in anti-seizure drug development with high predictability of...
Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy
February 22, 2024 08:30 ET
|
Avenue Therapeutics
MIAMI, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of...
AFCI Announces 2024 Board with New Leadership and Expanded Global Representation
January 30, 2024 18:31 ET
|
AFCI
The Association of Film Commissioners International (AFCI) today announced the election of members and officers for its 2024 board of directors.
Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference
January 11, 2024 08:00 ET
|
Avenue Therapeutics
MIAMI, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of...
Avenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in Proceeds
January 05, 2024 09:15 ET
|
Avenue Therapeutics
MIAMI, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of...
Avenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV Tramadol
January 04, 2024 08:30 ET
|
Avenue Therapeutics
MIAMI, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of...